Ostarine(MK-2866)

• Catalog No.: S1174
• CAS Number: 841205-47-8
• M. F.: C19H14F3N3O3
• M. W.: 389.3279696
• Storage: -20°C

SYNONYMS

• IUPAC name: (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
• IUPAC Traditional name: (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
• Synonyms: MK-2866; GTx-024

DATABASE IDS

• CAS Number: 841205-47-8

PROPERTIES

• Target: Androgen Receptor
• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Protocol

• Protocol: Kinase Assay ^[1]
• In vitro competitive radioligand binding assay: The AR binding affinity of Ostarine is determined using an in vitro competitive radioligand binding assay with [^3H]mibolerone (MIB). Briefly, increasing concentrations (0.01-5000 nM) of Ostarine are incubated with rat cytosol, a saturating concentration of [^3H]-MIB (1 nM), and 1000 nM triamcinolone acetonide to prevent interaction of MIB with progesterone receptors at 4 °C for 18 hours. At the end of incubation, free and bound [^3H]-MIB are separated using the hydroxyapatite method. IC50 value is determined by computer-fitting the data for each ligand by nonlinear regression analysis.
• Protocol: Animal Study ^[1]
• Animal Models: Immature castrated male Sprague-Dawley rats
• Formulation: Dissolved in DMSO, and diluted in saline
• Doses: 1 mg/day
• Administration: Subcutaneous injection

References

• References: [1] Kim J, et al. J Pharmacol Exp Ther, 2005, 315(1), 230-239.
• References: [2] Duke CB, et al. J Med Chem, 2011, 54(11), 3973-3976.

REFERENCES

• Kim J, et al. J Pharmacol Exp Ther, 2005, 315(1), 230-239.
• Duke CB, et al. J Med Chem, 2011, 54(11), 3973-3976.